gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Influence of the department on the resection rate in palliative treatment of metastatic colorectal cancer (CRC)

Meeting Abstract

  • corresponding author presenting/speaker Axel Wein - Medizinische Klinik 1, Universitätsklinikum Erlangen, Deutschland
  • Torsten Liersch - Chirurgische Universitätsklinik Göttingen
  • Ralf Hofheinz - Onkologisches Zentrum III: Medizinische Klinik, Universitätsklinikum Mannheim
  • Jörg Fahlke - Klinik für Allgemeine, Viszeral- u. Gefäßchirurgie,Otto-von-Guericke Universität Magdeburg
  • Jochen Wilke - Praxis für Hämatologie und Internistische Onkologie am Klinikum Fürth
  • Wolfgang M. Brueckl - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Gudrun Maennlein - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Ralf Kohnen - IMEREM, Institute for Medical Research Management and Biometrics, Nürnberg
  • Frank Boxberger - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Eckhart G. Hahn - Medizinische Klinik 1, Universitätsklinikum Erlangen
  • Werner Hohenberger - Chirurgische Klinik, Universitätsklinikum Erlangen

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO180

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Wein et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Background: During the last years due to the application of Irinotecan, Oxaliplatin and “biologicals” for the first- and secondline treatment of CRC in palliative situation the efficacy of palliative treatment has considerably improved with an acceptable toxicity. The achievements of secondary metastatic resection after downsizing by palliative treatment have increasingly become the focus of interest in palliative patients and opened up new ways in terms of curative options (Folprecht et al. 2005; Wein et al. 2001). Here, we analyse the influence of different departments on the resection rate after palliative treatment.

Methods: A prospective phase III trial in metastatic CRC with systemic treatment by 5-FU/sodium FA as a 24h-infusion (AIO) versus AIO plus Oxaliplatin followed by secondary metastatic resection. Trial start: 2000; end of trial: 2005. Randomized patients: n = 240 by 5 centers experienced in clinical trials including the respective local surgical departments. In order to achieve a homogeneous patient group, non-resectability of distant metastases was required according to pre-defined criteria. Stratification characteristics: In accordance to the participating departments; ECOG index 0,1 vs 2. Involvement of the hepatic tumour extension < 25% vs > 25% vs other localisation; organ manifestation 1 vs > 1. Inclusion criteria: Definitively non-resectable metastases. Palliative first-line treatment: Histologically proven adenocarcinoma of the colon or rectum, unambiguous enlargement of metastatic masses in objective imaging procedures. At least one bidimensionally measurable tumour lesion. Age: > 18, < 75 years. Exclusion criteria: Concomitant treatment with other anti-neoplastic substances. Sensoric neuropathy.

Results: Resected/randomized patients of 176 currently evaluable patients, both treatment groups combined: department (dep.) 01: 0/26 (0%), dep. 02: 10/27 (37,0%), dep. 03: 21/68 (30,9%), dep. 04: 8/43 (18,6%), dep. 05: 1/12 (8,3%), total: 40/176 (22.7%). Although in the total population, a remarkable resection rate could be achieved, the variation between the departments is high (p=.0043 for differences between departments).

Conclusions: The resection rate after palliative CRC treatment essentially depends on the department.